Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program

Public Health Reports

Volumn 122, Issue SUPPL. 2, 2007, Pages 83-88

  Klein, Susan J ^a   Wright, Lester N ^b   Birkhead, Guthrie S ^a,c   Mojica, Benjamin A ^d   Klopf, Linda C ^b   Klein, Laurence A ^a   Tanner, Ellen L ^a   Feldman, Ira S ^a   Fraleye, Edward J ^e  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b New York State Department of Correctional Services   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d NEW YORK CITY HEALTH AND HOSPITALS CORPORATION   (United States)

^e New York State Division of Parole   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH PROGRAM; HEALTH PROMOTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; MEDICAID; PATIENT MONITORING; PATIENT REFERRAL; PRIORITY JOURNAL; PRISON; UNITED STATES; HEALTH CARE DELIVERY; HOSPITAL MANAGEMENT; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PUBLIC HEALTH SERVICE;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; CONTINUITY OF PATIENT CARE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HIV INFECTIONS; HOSPITAL ADMINISTRATION; HUMANS; MEDICAID; NEW YORK; PRISONS; PUBLIC HEALTH PRACTICE; REFERRAL AND CONSULTATION;

EID: 34250334182     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/00333549071220s216     Document Type: Article

References (36)

1. Braithwaite RL, Hammett TM, Mayberry RM. Prisons and AIDS: a public health challenge. San Francisco: Jossey-Bass Publishers; 1996.
2. Glaser JB, Greifinger RB. Correctional health care: a public health opportunity. Ann Intern Med 1993;118:139-45.
3. Hammett TM. Public health/corrections collaborations: prevention and treatment of HIV/AIDS, STDs, and TB. Research in brief. Washington, DC: U.S. Department of Justice, Office of Justice Programs, National Institute of Justice; July 1998. Report No. NCJ 169590.
4. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002;92:1789-94.
5. Weinbaum CM, Lyerla R, Margolis HS; Centers for Disease Control and Prevention (US). Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep 2003;52(RR-1):1-36.
6. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005;19(Suppl 3):S41-6.
7. Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ 2000;321:78-82.
8. Boutwell AE, Allen SA, Rich JD. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005;40(Suppl 5):S367-72.
9. Fox RK, Currie SL, Evans J, Wright TL, Tobler L, Phelps B, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis 2005;41:177-86.
10. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004;94:1218-23.
11. Pradhan MM, Horswell R, Jones G, Ramsey JL, Cassidy W. Evaluation of The Federal Bureau of Prisons protocol for selection of which hepatitis C-infected inmates are considered for treatment. Dig Dis Sci 2005;50:714-8.
12. Theodore D, Dougherty KA, Smith P, Zacks S, Galanko J, Russo M, et al. Increasing liver-related mortality in incarcerated populations. Hepatology 2003;38:694A.
13. Association of State and Territorial Health Officials (ASTHO). Hepatitis C in incarcerated populations: the next wave for correctional health initiatives. Washington, DC: 2001.
14. Cassidy WM, Guidry D, Colton CE. Hepatitis C in corrections: testing treatment and co-infection. Infectious Diseases in Corrections Report 2005;8:1-3.
15. Macalino GE, Dhawan D, Rich JD. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 2005;95:1739-40.
16. National Institutes of Corrections (US). The health status of soon-to-be-released inmates: a report to Congress, Volume 1. Chicago, IL: NIC; 2002.
17. Reindollar RW. Hepatitis C and the correctional population. Am J Med 1999;107(6B):100S-103S.
18. Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 2005;95:1737-9.
19. Shaw FE, Beilenson W. Hepatitis C control in prisons remains an elusive goal. Hepatitis Control Report 1999;4:1-4.
20. Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004;81:719-34.
21. Beck AJ, Maruschak LM. Hepatitis testing and treatment in state prisons. Bureau of Justice Statistics Special Report. Washington, DC: Department of Justice (US); 2004; Report No.: NCJ 199173.
22. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med 1999;28:92-100.
23. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003;138:187-90.
24. Sterling RK, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. Treatment of chronic hepatitis C in the Virginia Department of Corrections: can compliance overcome racial differences to response? Am J Gastroenterol 2004;99:866-72.
25. Bennett WG, Pauker SG, Davis GL, Wong JB. Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C. Dig Dis Sci 1996;41(12 Suppl):56S-62S.
26. Dusheiko GM, Roberta JA. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995;22:1863-73.
27. Koff RS. Therapy of hepatitis C: cost-effectiveness analysis. Hepatology 1997;26(3 Suppl 1):152S-155S.
28. Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268-72.
29. Harrison PM, Beck AJ. Prisoners in 2004. Washington, DC: Department of Justice (US), Office of Justice Programs, Bureau of Justice Statistics Bulletin; 2005. Report No.: NCJ210677. Also available from: URL: http://www.ojp.usdoj. gov/bjs/pub/pdf/p04.pdf [cited 2006 Jan 18].
30. New York State Department of Correctional Services. HUB System: profile of inmate population under custody on January 1, 2004. Albany, NY: NYSDOCS; 2005.
31. Management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46. Also available from: URL: http://consensus.nih.gov/2002/ 2002HepatitisC2002116PDF.pdf [cited 2006 Jan 23].
32. Centers for Disease Control and Prevention (US). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998;47(RR-19):1-39.
33. Klein SJ, Gieryic SM, O'Connell DA, Hall JY, Klopf LC. Availability of HIV prevention services within New York State correctional facilities during 1999-2000: results of a survey. The Prison Journal 2002;82:69-83.
34. Klein SJ, O'Connell DA, Devore BS, Wright LN, Birkhead GS. Building an HIV continuum for inmates: New York State's criminal justice initiative. AIDS Educ Prev 2002;14(5 Suppl B):114-23.
35. Smith LC, Wang L, Wright L, Sabin KM, Glebatis D, Smith PF. Hepatitis C virus (HCV) seroprevalance among incoming inmates in New York State (NYS) 2000-2001. Poster presentation #793 at the Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24-27; Chicago, IL.
36. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006;144:762-9.